362225
β2-Glycoprotein 1, Human Plasma
Synonym(s):
Apolipoprotein H
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
NACRES:
NA.25
UNSPSC Code:
12352202
Form:
solid
Assay:
≥95% (SDS-PAGE)
assay
≥95% (SDS-PAGE)
Quality Level
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
concentration
≥2 PEU/mg solid (antigen content)
shipped in
ambient
storage temp.
2-8°C
General description
Native β2-glycoprotein 1 from human plasma. A carbohydrate-rich plasma protein that is a constituent of several lipoprotein particles. Possesses sialylated and galactosylated bi- and triantennary oligosaccharides.
Physical form
Lyophilized from 200 mM glycine, 150 mM NaCl, pH 7.5.
Preparation Note
Prepared from plasma that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
Following reconstitution, store in the refrigerator (4°C). Stock solutions are stable for 1 month at 4°C or for up to 4 h at 20°C.
Reconstitute with 1 ml of distilled H₂O.
Other Notes
One PEU is defined as the amount of β₂-glycoprotein 1 present in 1 ml of normal plasma (~200 µg).
Wang, S.X., et al. 1999. Biochemistry 38, 9477.
Cassader, M., et al. 1994. Artherosclerosis 110, 45.
Walsh, M.T., et al. 1990. Biochem. 29, 6250.
Cassader, M., et al. 1994. Artherosclerosis 110, 45.
Walsh, M.T., et al. 1990. Biochem. 29, 6250.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
Storage Class
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Xue Jing et al.
Oncology reports, 40(2), 1035-1045 (2018-06-20)
Chronic hepatitis B virus (HBV) infection remains one of the leading causes of hepatocellular carcinoma (HCC) globally. However, the mechanism underlying the mediation by HBV surface proteins (HBsAgs) of the early steps in the virus life cycle and following HCC development